

Patent Docket P1071P2D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Chen et al. Serial No.: 09/723,185	Group Art Unit: 1647 Examiner: David Romeo
Filed: 27 November 2000 For: INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES	CERTIFICATE OF FACSIMILE TRANSMISSION November 8, 2002 Date of Transmission I hereby certify that this correspondence, consisting of Third Preliminary Amendment and Communication Amendment transmitted, and Supplemental Application Data Sheet, is being facsimile transmitted to the Assistant Commissioner of Patents, Washington, D.C. 20231. <i>Janet E. Hasak</i> Janet E. Hasak

10/D
 M.G.J
 11/14/02

THIRD PRELIMINARY AMENDMENT AND COMMUNICATION

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows.

IN THE CLAIMS:

Please cancel claims 31-44 and 46.

REMARKS

Claims 31-44 and 46 are hereby canceled, as they are presented in the sister application, U.S. Ser. No. 09/723,254. In that application, canceled claims 27-30 were restricted from elected claims 31-44 and 46.

Applicants hereby clarify for the record that the claims presented in this application are directed to Group II of the inventions set forth in the restriction requirement within the Office Action dated March 26, 2001 in the immediate parent application Ser. No. 09/337,227. Specifically, in that Office Action, the Examiner required restriction to one of the following inventions under 35 USC §121:

I. Claims 1-26, 45, 47-49, and 51, drawn to peptides falling under the generic sequence of SEQ ID NO:1 (claim 1); and